Targeting Long Noncoding RNA H19 in Subchondral Bone Osteocytes and the Alleviation of Cartilage Degradation in Osteoarthritis
Authors:
Open Access
- 8 January 2025
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (3) , 283-297
Abstract
Objective: Emerging evidence suggests long noncoding RNA H19 is associated with osteoarthritis (OA) pathology. However, how H19 contributes to OA has not been reported. This study aims to investigate the biologic function of H19 in OA subchondral bone remodeling and OA progression.Methods: Clinical joint samples and OA animal models induced by surgical destabilization of the medial meniscus (DMM) were used to verify the causal relationship between osteocyte H19 and OA subchondral bone and cartilage changes. MLO‐Y4 osteocyte cells subjected to fluid shear stress were used to verify the mechanism underlying H19‐mediated mechanoresponse. Finally, the antisense oligonucleotide (ASO) against H19 was delivered to mice knee joints by magnetic metal–organic framework (MMOF) nanoparticles to develop a site‐specific delivery method for targeting osteocyte H19 for OA treatment.Results: Both clinical OA subchondral bone and wildtype mice with DMM‐induced OA exhibit aberrant higher subchondral bone mass, with more H19 mice expressing osteocytes. On the contrary, mice with osteocyte‐specific deletion of H19 are less vulnerable to DMM‐induced OA phenotype. In MLO‐Y4 cells, H19‐mediated osteocyte mechanoresponse through PI3K/AKT/GSK3 signal activation by EZH2‐induced H3K27me3 regulation on protein phosphatase 2A inhibition. Targeted inhibition of H19 (using ASO‐loaded MMOF) substantially alleviates subchondral bone remodeling and OA phenotype.Conclusion: In summary, our results provide new evidence that the elevated H19 expression in osteocytes may contribute to aberrant subchondral bone remodeling and OA progression. H19 appears to be required for the osteocyte response to mechanical stimulation, and targeting H19 represents a new promising approach for OA treatment. imageKeywords
This publication has 53 references indexed in Scilit:
- Radicals Scavenging MOFs Enabling Targeting Delivery of siRNA for Rheumatoid Arthritis TherapySmall, 2022
- Long non-coding RNAs: From disease code to drug roleActa Pharmaceutica Sinica B, 2021
- Mechanosensitive Control of Articular Cartilage and Subchondral Bone Homeostasis in Mice Requires Osteocytic Transforming Growth Factor β SignalingArthritis & Rheumatology, 2021
- Engineering a Nanoscale Al‐MOF‐Armored Antigen Carried by a “Trojan Horse”‐Like Platform for Oral Vaccination to Induce Potent and Long‐Lasting ImmunityAdvanced Functional Materials, 2019
- Metal–Organic Framework‐Based Stimuli‐Responsive Systems for Drug DeliveryAdvanced Science, 2018
- Blocking PI3K/AKT signaling inhibits bone sclerosis in subchondral bone and attenuates post‐traumatic osteoarthritisJournal of Cellular Physiology, 2018
- Regulation of H19 and its encoded microRNA-675 in osteoarthritis and under anabolic and catabolic in vitro conditionsJournal of Molecular Medicine, 2012
- The amazing osteocyteJournal of Bone and Mineral Research, 2010
- Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the β-catenin and PKA pathwaysJournal of Bone and Mineral Research, 2010
- Osteocytes, mechanosensing and Wnt signalingBone, 2008